Literature DB >> 29382967

Comparison of 3 vaccination strategies against porcine reproductive and respiratory syndrome virus, Mycoplasma hyopneumoniae, and porcine circovirus type 2 on a 3 pathogen challenge model.

Jiwoon Jeong1, Ikjae Kang1, Seeun Kim1, Kee Hwan Park1, Changhoon Park1, Chanhee Chae1.   

Abstract

The objective of this study was to compare clinical, microbiologic, immunologic, and pathologic parameters in pigs each concurrently administered porcine reproductive and respiratory syndrome virus (PRRSV), Mycoplasma hyopneumoniae, and porcine circovirus type 2 (PCV2) vaccine from 1 of 2 commercial sources at 21 days of age and challenged with field strains of each of the 3 pathogens. Pigs were challenged with PRRSV and M. hyopneumoniae at 42 days of age (-14 days post-challenge, dpc) followed by a challenge with PCV2 at 56 days of age (0 dpc). Significant differences were observed between vaccinated challenged and unvaccinated challenged groups in clinical (average daily gain and clinical signs), microbiologic (viremia and nasal shedding), immunologic (antibodies and interferon-γ secreting cells), and pathologic (lesions) outcomes. Significant differences were observed among the 3 vaccinated challenged groups in microbiologic (nasal shedding of M. hyopneumoniae and viremia of PCV2) and immunologic (M. hyopneumoniae- and PCV2-specific interferon-γ secreting cells) outcomes. The vaccination regimen for PRRSV vaccine, M. hyopneumoniae vaccine, and PCV2 vaccine is efficacious for controlling triple challenge with PRRSV, M. hyopneumoniae, and PCV2 from weaning to finishing period.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29382967      PMCID: PMC5764041     

Source DB:  PubMed          Journal:  Can J Vet Res        ISSN: 0830-9000            Impact factor:   1.310


  36 in total

Review 1.  Immunological solutions for treatment and prevention of porcine reproductive and respiratory syndrome (PRRS).

Authors:  Michael P Murtaugh; Marika Genzow
Journal:  Vaccine       Date:  2011-09-17       Impact factor: 3.641

2.  Comparative efficacy of commercial Mycoplasma hyopneumoniae and porcine circovirus 2 (PCV2) vaccines in pigs experimentally infected with M. hyopneumoniae and PCV2.

Authors:  D Kim; C H Kim; K Han; H W Seo; Y Oh; C Park; I Kang; C Chae
Journal:  Vaccine       Date:  2011-02-24       Impact factor: 3.641

3.  Comparison of the antigen distribution of two US porcine reproductive and respiratory syndrome virus isolates with that of the Lelystad virus.

Authors:  P G Halbur; P S Paul; M L Frey; J Landgraf; K Eernisse; X J Meng; J J Andrews; M A Lum; J A Rathje
Journal:  Vet Pathol       Date:  1996-03       Impact factor: 2.221

4.  Reduction of economic losses caused by mycoplasmal pneumonia of pigs by vaccination with Respisure and by Tiamutin treatment.

Authors:  L Stipkovits; Zs Laky; T Abonyi; Jurate Siugzdaite; I Szabó
Journal:  Acta Vet Hung       Date:  2003       Impact factor: 0.955

Review 5.  Commercial porcine circovirus type 2 vaccines: efficacy and clinical application.

Authors:  Chanhee Chae
Journal:  Vet J       Date:  2012-07-28       Impact factor: 2.688

6.  Efficacy of a reformulated inactivated chimeric PCV1-2 vaccine based on clinical, virological, pathological and immunological examination under field conditions.

Authors:  Hwi Won Seo; Kiwon Han; Yeonsu Oh; Changhoon Park; Chanhee Chae
Journal:  Vaccine       Date:  2012-09-07       Impact factor: 3.641

7.  Comparison of 2 commercial single-dose Mycoplasma hyopneumoniae vaccines and porcine reproductive and respiratory syndrome virus (PRRSV) vaccines on pigs dually infected with M. hyopneumoniae and PRRSV.

Authors:  Changhoon Park; Ikjae Kang; Hwi Won Seo; Jiwoon Jeong; Kyuhyung Choi; Chanhee Chae
Journal:  Can J Vet Res       Date:  2016-04       Impact factor: 1.310

8.  Comparison of the pathogenicity of two US porcine reproductive and respiratory syndrome virus isolates with that of the Lelystad virus.

Authors:  P G Halbur; P S Paul; M L Frey; J Landgraf; K Eernisse; X J Meng; M A Lum; J J Andrews; J A Rathje
Journal:  Vet Pathol       Date:  1995-11       Impact factor: 2.221

9.  Evaluation of the efficacy of a new modified live porcine reproductive and respiratory syndrome virus (PRRSV) vaccine (Fostera PRRS) against heterologous PRRSV challenge.

Authors:  Changhoon Park; Hwi Won Seo; Kiwon Han; Ikjae Kang; Chanhee Chae
Journal:  Vet Microbiol       Date:  2014-06-06       Impact factor: 3.293

10.  Interaction between single-dose Mycoplasma hyopneumoniae and porcine reproductive and respiratory syndrome virus vaccines on dually infected pigs.

Authors:  Su-Jin Park; Hwi Won Seo; Changhoon Park; Chanhee Chae
Journal:  Res Vet Sci       Date:  2014-04-02       Impact factor: 2.534

View more
  8 in total

1.  A Comparative Field Evaluation of the Effect of Growth Performance Between Porcine Circovirus Type 2a (PCV2a)- and PCV2b-Based Bivalent Vaccines Containing PCV2 and Mycoplasma hyopneumoniae.

Authors:  Hyejean Cho; Taehwan Oh; Jeongmin Suh; Chanhee Chae
Journal:  Front Vet Sci       Date:  2022-06-24

2.  Comparative growth performance of 3 types of combination vaccines containing porcine circovirus 2 and Mycoplasma hyopneumoniae under field conditions.

Authors:  Siyeon Yang; Joo Young Lee; Taehwan Oh; Kee Hwan Park; Hyejean Cho; Jeongmin Suh; Kyung-Duk Min; Hee Jin Ham; Chanhee Chae
Journal:  Can J Vet Res       Date:  2022-04       Impact factor: 0.897

3.  Efficacy comparison of commercial porcine circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae monovalent and bivalent vaccines against a dual challenge.

Authors:  Siyeon Yang; Su-Jin Park; Taehwan Oh; Hyejean Cho; Chanhee Chae
Journal:  Can J Vet Res       Date:  2020-10       Impact factor: 1.310

4.  A field efficacy trial of a trivalent vaccine containing porcine circovirus type 2a and 2b, and Mycoplasma hyopneumoniae in three herds.

Authors:  Hyungmin Um; Siyeon Yang; Taehwan Oh; Hyejean Cho; Kee Hwan Park; Jeongmin Suh; Chanhee Chae
Journal:  Vet Med Sci       Date:  2021-10-22

5.  Evaluation of the efficacy of a trivalent vaccine mixture against a triple challenge with Mycoplasma hyopneumoniae, PCV2, and PRRSV and the efficacy comparison of the respective monovalent vaccines against a single challenge.

Authors:  Taehwan Oh; Kee Hwan Park; Siyeon Yang; Jiwoon Jeong; Ikjae Kang; Changhoon Park; Chanhee Chae
Journal:  BMC Vet Res       Date:  2019-10-16       Impact factor: 2.741

6.  miR‑146a‑5p suppresses ATP‑binding cassette subfamily G member 1 dysregulation in patients with refractory Mycoplasma pneumoniae via interleukin 1 receptor‑associated kinase 1 downregulation.

Authors:  Hu-Nian Li; Xu Zhao; Yong-Jiu Zha; Fang Du; Jie Liu; Liang Sun
Journal:  Int J Mol Med       Date:  2019-10-22       Impact factor: 4.101

7.  Development of a Combined Genetic Engineering Vaccine for Porcine Circovirus Type 2 and Mycoplasma Hyopneumoniae by a Baculovirus Expression System.

Authors:  Yu Tao; Gaojian Li; Wenqian Zheng; Jianhong Shu; Jian Chen; Fang Yang; Yuehong Wu; Yulong He
Journal:  Int J Mol Sci       Date:  2019-09-09       Impact factor: 5.923

8.  Optimal vaccination strategy against Mycoplasma hyopneumoniae, porcine reproductive and respiratory syndrome virus, and porcine circovirus type 2 in case of early M. hyopneumoniae infection.

Authors:  Siyeon Yang; Taehwan Oh; Josuke Mago; Akihiro Iwakuma; Chanhee Chae
Journal:  Vet Med Sci       Date:  2020-05-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.